论文部分内容阅读
血栓素A2的增高与动脉硬化的发生密切相关,近年来对于血栓素受体的实验研究显示,阿司匹林虽然能抑制血栓素A2的产生,但是不能显著抑制动脉斑块的形成,而应用血栓素受体拮抗剂不但能显著减小粥样斑块的面积,还可以改变斑块内细胞组成成分,使得斑块更加稳定。因此提出血栓素受体较血栓素A2与动脉粥样硬化的关系更为密切,并且可作为治疗的靶点。本文将近年来有关这方面的实验研究加以总结,以提高对动脉硬化发生机制的进一步认识。
The increase of thromboxane A2 is closely related to the occurrence of atherosclerosis. In recent years, experimental studies on thromboxane receptor have shown that although aspirin can inhibit the production of thromboxane A2, it can not significantly inhibit the formation of arterial plaque, but thromboxane receptor Body antagonists not only significantly reduce the area of atherosclerotic plaque, but also can change the cell components within the plaque, making the plaque more stable. Therefore, it is suggested that thromboxane receptor is more closely related to atherosclerosis than thromboxane A2, and may be used as a therapeutic target. This article summarizes the experimental research in this area in recent years in order to improve the understanding of the mechanism of atherosclerosis.